Cartesian Therapeutics, Inc. (RNAC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q3 '16: 7.3M Q4 '16: 8.1M Q1 '17: 6.1M Q2 '17: 4.1M Q3 '17: 3.1M Q4 '17: 207K Q1 '18: 70K Q2 '18: 44K Q3 '18: 17K Q4 '18: 903K Q1 '19: 913K Q2 '19: 926K Q3 '19: 926K Q4 '19: 6.7M Q1 '20: 6.7M Q2 '20: 6.7M Q3 '20: 11.3M Q4 '20: 16.6M Q1 '21: 27.6M Q2 '21: 47.3M Q3 '21: 67.1M Q4 '21: 85.1M Q1 '22: 108M Q2 '22: 127.6M Q3 '22: 123.9M Q4 '22: 110.8M Q1 '23: 82.7M Q2 '23: 48.7M Q3 '23: 34.5M Q4 '23: 26M Q1 '24: 25.9M Q2 '24: 54.1M Q3 '24: 47.9M Q4 '24: 38.9M Q1 '25: 34.2M Q2 '25: 1M Q3 '25: 1.1M Q4 '25: 2.8M Q1 '26: 1.8M Q2 '26: 1.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '16: -27.9M Q4 '16: -34.7M Q1 '17: -42.5M Q2 '17: -52M Q3 '17: -58.4M Q4 '17: -63.8M Q1 '18: -64.8M Q2 '18: -67.7M Q3 '18: -69.8M Q4 '18: -65M Q1 '19: -61.1M Q2 '19: -58.5M Q3 '19: -54.4M Q4 '19: -52.5M Q1 '20: -59.4M Q2 '20: -59.6M Q3 '20: -61.5M Q4 '20: -56.8M Q1 '21: -45.2M Q2 '21: -28.3M Q3 '21: -16.6M Q4 '21: -4.6M Q1 '22: 13.3M Q2 '22: 26.7M Q3 '22: 27.1M Q4 '22: 14.5M Q1 '23: -14.6M Q2 '23: -47.1M Q3 '23: -58.6M Q4 '23: -86.4M Q1 '24: -81.4M Q2 '24: -49M Q3 '24: -53.5M Q4 '24: -43.9M Q1 '25: -52.4M Q2 '25: -88M Q3 '25: -91.5M Q4 '25: -143.4M Q1 '26: -148M Q2 '26: -155.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q3 '16: -29M Q4 '16: -36.2M Q1 '17: -43.9M Q2 '17: -52.9M Q3 '17: -59.9M Q4 '17: -65.3M Q1 '18: -66.1M Q2 '18: -68.9M Q3 '18: -70.2M Q4 '18: -65.3M Q1 '19: -61.5M Q2 '19: -59.1M Q3 '19: -55.1M Q4 '19: -55.4M Q1 '20: -62.9M Q2 '20: -70.6M Q3 '20: -68.3M Q4 '20: -68.9M Q1 '21: -73.9M Q2 '21: -45.2M Q3 '21: -53.4M Q4 '21: -25.7M Q1 '22: 27.7M Q2 '22: 31.7M Q3 '22: 41.7M Q4 '22: 42.7M Q1 '23: -7.7M Q2 '23: -27.7M Q3 '23: -28.8M Q4 '23: -219.7M Q1 '24: -254.9M Q2 '24: -229.6M Q3 '24: -244.8M Q4 '24: -77.4M Q1 '25: -38.3M Q2 '25: -36.3M Q3 '25: -48M Q4 '25: -130.3M Q1 '26: -151.8M Q2 '26: -151.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -28.9M Q4 '16: -19.8M Q1 '17: -24.9M Q2 '17: -27.9M Q3 '17: -37.9M Q4 '17: -52M Q1 '18: -50.1M Q2 '18: -58.5M Q3 '18: -59.1M Q4 '18: -59.2M Q1 '19: -66M Q2 '19: -56.2M Q3 '19: -51.3M Q4 '19: -51.4M Q1 '20: -42.9M Q2 '20: -47.5M Q3 '20: 29.3M Q4 '20: 34.9M Q1 '21: 34.4M Q2 '21: 40.2M Q3 '21: -36.2M Q4 '21: -60.4M Q1 '22: -60.1M Q2 '22: -66.3M Q3 '22: -51.2M Q4 '22: -31.6M Q1 '23: -28.5M Q2 '23: -26.2M Q3 '23: -39.7M Q4 '23: -51.2M Q1 '24: -58.3M Q2 '24: -62.9M Q3 '24: -40M Q4 '24: -23.7M Q1 '25: -30.9M Q2 '25: -33.9M Q3 '25: -63.2M Q4 '25: -73.9M Q1 '26: -73M Q2 '26: -76.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -29.5M Q4 '16: -20.3M Q1 '17: -25.4M Q2 '17: -28.8M Q3 '17: -38.6M Q4 '17: -52.8M Q1 '18: -51M Q2 '18: -59.2M Q3 '18: -59.7M Q4 '18: -60M Q1 '19: -66.7M Q2 '19: -56.6M Q3 '19: -51.7M Q4 '19: -51.5M Q1 '20: -43.1M Q2 '20: -47.9M Q3 '20: 28.6M Q4 '20: 34.1M Q1 '21: 33.7M Q2 '21: 39.1M Q3 '21: -37.2M Q4 '21: -61.5M Q1 '22: -61.6M Q2 '22: -67.3M Q3 '22: -52.5M Q4 '22: -32.8M Q1 '23: -29.4M Q2 '23: -26.9M Q3 '23: -40.1M Q4 '23: -51.4M Q1 '24: -59M Q2 '24: -65.1M Q3 '24: -48.4M Q4 '24: -32.8M Q1 '25: -40.4M Q2 '25: -44.5M Q3 '25: -68.9M Q4 '25: -79.4M Q1 '26: -77.4M Q2 '26: -78.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 96.8M Q3 '20: 105.3M Q1 '21: 110.7M Q2 '21: 121.2M Q3 '21: 115.2M Q1 '22: 127.6M Q2 '22: 148.5M Q3 '22: 152.8M Q1 '23: 5.1M Q2 '23: 5.1M Q3 '23: 5.2M Q1 '24: 5.4M Q2 '24: 17.8M Q3 '24: 21.5M Q1 '25: 25.9M Q2 '25: 26.4M Q3 '25: 26M Q1 '26: 26.9M Q2 '26: 29.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '15: -15.12 Q1 '16: -16.21 Q2 '16: -15.03 Q3 '16: -11.96 Q4 '16: -8.47 Q1 '17: -4.77 Q2 '17: -2.87 Q3 '17: -3.10 Q4 '17: -3.21 Q1 '18: -3.10 Q2 '18: -3.09 Q3 '18: -3.14 Q4 '18: -2.91 Q1 '19: -2.51 Q2 '19: -2.04 Q3 '19: -1.59 Q4 '19: -1.22 Q1 '20: -1.12 Q2 '20: -1.00 Q3 '20: -0.83 Q4 '20: -0.69 Q1 '21: -0.70 Q2 '21: -0.45 Q3 '21: -0.52 Q4 '21: -0.22 Q1 '22: 0.08 Q2 '22: 0.14 Q3 '22: 0.25 Q4 '22: 0.10 Q1 '23: -4.22 Q2 '23: -6.51 Q3 '23: -8.20 Q4 '23: -49.77 Q1 '24: -56.03 Q2 '24: -53.26 Q3 '24: -52.65 Q4 '25: -5.13 Q1 '26: -5.91 Q2 '26: -5.95 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.